If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
90.00    0.00 (0.00%)
Bid:
85.00
Ask:
95.00
Spread: 10.00 (11.765%)
Market Cap: £5.92m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
14th Sep 20202:06 pmRNSHolding(s) in Company
30th Jun 202011:53 amRNSResult of AGM and Trading Update
15th Jun 202010:42 amRNSSignificant Contract Win
9th Jun 20204:06 pmRNSAnnual Report and Notice of AGM
7th May 20207:11 amRNSPreliminary Results
4th May 20204:05 pmRNSDIRECTOR RESIGNATION
1st Apr 20203:30 pmRNSHolding(s) in Company
30th Mar 20207:00 amRNSStatement regarding Coronavirus
13th Mar 20207:00 amRNSChange of Adviser
25th Feb 20208:19 amRNSHolding(s) in Company
18th Feb 20207:00 amRNSSignificant contract wins in the rail sector
28th Jan 202010:43 amRNSHolding(s) in Company
3rd Jan 20209:17 amRNSHolding(s) in Company
23rd Dec 20197:00 amRNSSignificant long-term contract and trading update
1st Oct 20197:00 amRNSSignificant long-term contract win
27th Sep 20197:00 amRNSInterim Results
1st Jul 20197:00 amRNSDirector and Company Secretary Appointment
28th Jun 20193:02 pmRNSResult of AGM
27th Jun 20197:00 amRNSContract Wins and New Partnerships
7th Jun 20197:00 amRNSFinal Results and Notice of AGM
17th May 20197:00 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSPreliminary Announcement of Results to 31/12/18
16th Apr 20199:20 amRNSHolding(s) in Company
1st Mar 20192:56 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSContract Wins in the rail sector
29th Jan 20197:00 amRNSTrading Update
2nd Nov 20182:08 pmRNSExercise Of Options
4th Oct 20184:47 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSInterim Results
20th Sep 20187:00 amRNSContract Wins and Recruitment
5th Jul 20188:38 amRNSmpro5 healthcare update
2nd Jul 201811:21 amRNSResult of AGM
7th Jun 20188:28 amRNSFinal Results and Notice of AGM
24th Apr 20187:00 amRNSChange of Adviser
13th Apr 20187:00 amRNSPreliminary Results to 31 December 2017
28th Mar 20187:00 amRNSAppointment of new CEO
27th Feb 20187:00 amRNSTrading Statement
19th Dec 20173:44 pmRNSDirector/PDMR Shareholding
15th Dec 201711:30 amRNSExercise of Options
8th Dec 20173:37 pmRNSResult of GM
23rd Nov 20177:00 amRNSNotice of GM
24th Oct 20177:00 amRNSSeries of contract wins for mpro5
17th Oct 20177:00 amRNSDirectorate Change
7th Sep 20177:00 amRNSInterim Results
11th Jul 20177:00 amRNSSignificant mpro5 Contract Win in the Netherlands
29th Jun 20175:47 pmRNSResult of AGM
6th Jun 20172:00 pmRNSFinal Results and Notice of AGM
30th May 20177:00 amRNSInternational Expansion Update
30th Mar 20177:00 amRNSPreliminary Results
2nd Feb 20177:00 amRNSUpdate on International Expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.